论文部分内容阅读
我们采用免疫组化技术,检测50例原发性乳腺癌p16和cerbB2蛋白的表达情况。结果显示:17例(3400%)p16蛋白表达阳性,24例(4800%)cerbB2蛋白表达阳性。p16蛋白表达与乳腺癌的临床病理因素及预后无明显相关性。cerbB2蛋白表达在有淋巴结转移的乳腺癌中较多见(p=00237),且5年生存率低于阴性组(P=00169)。p16和cerbB2蛋白表达之间不存在一致性关系。结论:cerbB2蛋白表达在乳腺癌伴淋巴结转移中较多见,并降低远期生存率。
We used immunohistochemistry to detect the expression of p16 and cerbB2 protein in 50 cases of primary breast cancer. The results showed that: 17 cases (3400%) p16 protein expression was positive, 24 cases (4800%) cerbB2 protein expression was positive. There was no significant correlation between p16 protein expression and clinicopathological factors and prognosis of breast cancer. CerbB2 protein expression was more common in breast cancer with lymph node metastasis (p = 00237), and the 5-year survival rate was lower than that in the negative group (P = 00169). There is no consistent relationship between p16 and cerbB2 protein expression. Conclusion: cerbB2 protein expression is more common in breast cancer with lymph node metastasis, and reduce the long-term survival rate.